Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

被引：0
|
作者：
Siegel, David [1 ]
Jagannath, Sundar [2 ]
Lonial, Sagar [3 ]
Dimopoulos, Meletios A. [4 ]
Graef, Thorsten [5 ]
Pietrangelo, Dina [5 ]
Lupinacci, Lisa [5 ]
Reiser, David [5 ]
Rizvi, Syed [5 ]
Anderson, Kenneth C. [6 ]
机构：
[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[2] St Vincent Catholic Med Ctr, New York, NY USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[4] Univ Athens, Dept Therapeut, Athens, Greece
[5] Merck & Co Inc, Upper Gwynedd, PA USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1497 / 1497
页数：1
相关论文
共 50 条
  • [1] An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
    Alodhaibi, Ibrahim
    Ailawadhi, Sikander
    Burbano, Gabriel P.
    O'Brien, Patrick J.
    Buadi, Francis K.
    Hayman, Suzanne
    Kumar, Shaji K.
    Gonsalves, Wilson I.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (05): : 298 - 304
  • [2] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
    Badros, Ashraf
    Burger, Angelika M.
    Philip, Sunita
    Niesvizky, Ruben
    Kolla, Sarah S.
    Goloubeva, Olga
    Harris, Carolynn
    Zwiebel, James
    Wright, John J.
    Espinoza-Delgado, Igor
    Baer, Maria R.
    Holleran, Julianne L.
    Egorin, Merrill J.
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5250 - 5257
  • [4] COMBINED VORINOSTAT AND BORTEZOMIB IN BORTEZOMIB-REFRACTORY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INTERIM ANALYSIS OF A PHASE IIB STUDY
    Siegel, D.
    Jagannath, S.
    Lonial, S.
    Dimopoulos, M.
    Yoon, S. S.
    Graef, T.
    Pitrangelo, D.
    Lupinacci, L.
    Reiser, D.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 156 - 157
  • [5] VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
    Siegel, David S.
    Dimopoulos, Meletios
    Jagannath, Sundar
    Goldschmidt, Hartmut
    Durrant, Simon
    Kaufman, Jonathan L.
    Leleu, Xavier
    Nagler, Arnon
    Offner, Fritz
    Graef, Thorsten
    Eid, Joseph E.
    Houp, Jennifer
    Gause, Christine
    Vuocolo, Scott
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06): : 329 - +
  • [6] Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
    Gonsalves, Wilson I.
    Kumar, Shaji
    Perez, Gabriela
    Saathoff, Stephanie
    Wilson, Diana M.
    Young, Anna
    Ailawadhi, Sikander
    BLOOD, 2021, 138
  • [7] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
    Grammatico, Sara
    Bringhen, Sara
    Vozella, Federico
    Siniscalchi, Agostina
    Boccadoro, Mario
    Petrucci, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
  • [9] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Jacob P. Laubach
    Sascha A. Tuchman
    Jacalyn M. Rosenblatt
    Constantine S. Mitsiades
    Kathleen Colson
    Kelly Masone
    Diane Warren
    Robert A. Redd
    Dena Grayson
    Paul G. Richardson
    Blood Cancer Journal, 11
  • [10] Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
    Siegel, David S.
    Jagannath, Sundar
    Hajek, Roman
    Dimopoulos, Meletios A.
    Yoon, Sung-Soo
    Lonial, Sagar
    Laubach, Jacob P.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 813 - 814
12345